Vertex Pharmaceuticals (VRTX) Return on Invested Capital (2012 - 2025)

Vertex Pharmaceuticals' Return on Invested Capital history runs 12 years deep, the most recent figure standing at 0.19% for Q3 2025.

• On a quarterly basis, Return on Invested Capital rose 18.0% year-over-year to 0.19% in Q3 2025; TTM through Sep 2025 was 0.19%, a 18.0% increase from a year earlier, with the FY2024 full-year figure at 0.02%, down 5.0% from the prior year.
• Return on Invested Capital climbed to 0.19% in Q3 2025 per VRTX's latest filing, from 0.14% in the prior quarter.
• Across five years, Return on Invested Capital topped out at 0.19% in Q3 2025 and bottomed at 0.1% in Q1 2025.
• The 5-year median for Return on Invested Capital is 0.06% (2022), against an average of 0.05%.
• Biggest YoY gain for Return on Invested Capital was 18 bps in 2025; the steepest drop was 19 bps in 2025.
• Year by year, Return on Invested Capital stood at 0.04% in 2021, then jumped by 57 bps to 0.07% in 2022, then grew by 7 bps to 0.07% in 2023, then plunged by 82 bps to 0.01% in 2024, then soared by 1349 bps to 0.19% in 2025.
• Per Business Quant, the three latest VRTX Return on Invested Capital figures stand at 0.19% (Q3 2025), 0.14% (Q2 2025), and 0.1% (Q1 2025).